142 related articles for article (PubMed ID: 36682944)
1. Consensus statement and clinical pathway for the management of colon cancer with peritoneal metastases in the state of Delaware.
Esquivel J; Petrelli N; Spellman J; Bennett J; Chirla S; Khatri J; Masters G;
Surg Oncol; 2023 Dec; 51():101895. PubMed ID: 36682944
[TBL] [Abstract][Full Text] [Related]
2. The American Society of Peritoneal Surface Malignancies (ASPSM) Multiinstitution Evaluation of the Peritoneal Surface Disease Severity Score (PSDSS) in 1,013 Patients with Colorectal Cancer with Peritoneal Carcinomatosis.
Esquivel J; Lowy AM; Markman M; Chua T; Pelz J; Baratti D; Baumgartner JM; Berri R; Bretcha-Boix P; Deraco M; Flores-Ayala G; Glehen O; Gomez-Portilla A; González-Moreno S; Goodman M; Halkia E; Kusamura S; Moller M; Passot G; Pocard M; Salti G; Sardi A; Senthil M; Spilioitis J; Torres-Melero J; Turaga K; Trout R
Ann Surg Oncol; 2014 Dec; 21(13):4195-201. PubMed ID: 24854493
[TBL] [Abstract][Full Text] [Related]
3. Colorectal Peritoneal Metastases Treated by Perioperative Systemic Chemotherapy and Cytoreductive Surgery With or Without Mitomycin C-Based HIPEC: A Comparative Study Using the Peritoneal Surface Disease Severity Score (PSDSS).
Baratti D; Kusamura S; Azmi N; Guaglio M; Montenovo M; Deraco M
Ann Surg Oncol; 2020 Jan; 27(1):98-106. PubMed ID: 31691116
[TBL] [Abstract][Full Text] [Related]
4. P.R.O.P.S. - A novel Pre-Operative Predictive Score for unresectability in patients with colorectal peritoneal metastases being considered for cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC).
Yong ZZ; Tan GHC; Shannon N; Chia C; Teo MCC
World J Surg Oncol; 2019 Aug; 17(1):138. PubMed ID: 31391066
[TBL] [Abstract][Full Text] [Related]
5. RAS Mutation Decreases Overall Survival After Optimal Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy of Colorectal Peritoneal Metastasis: A Modification Proposal of the Peritoneal Surface Disease Severity Score.
Arjona-Sanchez A; Rodriguez-Ortiz L; Baratti D; Schneider MA; Gutiérrez-Calvo A; García-Fadrique A; Tuynman JB; Cascales-Campos PA; Martín VC; Morales R; Salti GI; Arteaga X; Pacheco D; Alonso-Gomez J; Yalkin O; Villarejo-Campos P; Sanchez-Hidalgo JM; Casado-Adam A; Cosano-Alvarez A; Rufian-Peña S; Briceño J
Ann Surg Oncol; 2019 Aug; 26(8):2595-2604. PubMed ID: 31111351
[TBL] [Abstract][Full Text] [Related]
6. [Construction and evaluation of a nomogram for predicting the prognosis of patients with colorectal cancer with peritoneal carcinomatosis treated with cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy].
An SL; Ji ZH; Li XB; Liu G; Zhang YB; Gao C; Zhang K; Zhang XJ; Yan GJ; Yan LJ; Li Y
Zhonghua Wei Chang Wai Ke Za Zhi; 2023 May; 26(5):434-441. PubMed ID: 37217351
[No Abstract] [Full Text] [Related]
7. Evolution of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Colorectal Peritoneal Metastases: 8-Year Single-Institutional Experience.
Narasimhan V; Britto M; Pham T; Warrier S; Naik A; Lynch AC; Michael M; Tie J; Ramsay R; Heriot A
Dis Colon Rectum; 2019 Oct; 62(10):1195-1203. PubMed ID: 31490828
[TBL] [Abstract][Full Text] [Related]
8. The American Society of Peritoneal Surface Malignancies Multi-Institution evaluation of 1,051 advanced ovarian cancer patients undergoing cytoreductive surgery and HIPEC: An introduction of the peritoneal surface disease severity score.
Foster JM; Sleightholm R; Smith L; Ceelen W; Deraco M; Yildirim Y; Levine E; Muñoz-Casares C; Glehen O; Patel A; Esquivel J
J Surg Oncol; 2016 Dec; 114(7):779-784. PubMed ID: 27792292
[TBL] [Abstract][Full Text] [Related]
9. The American Society of Peritoneal Surface Malignancies evaluation of HIPEC with Mitomycin C versus Oxaliplatin in 539 patients with colon cancer undergoing a complete cytoreductive surgery.
Prada-Villaverde A; Esquivel J; Lowy AM; Markman M; Chua T; Pelz J; Baratti D; Baumgartner JM; Berri R; Bretcha-Boix P; Deraco M; Flores-Ayala G; Glehen O; Gomez-Portilla A; González-Moreno S; Goodman M; Halkia E; Kusamura S; Moller M; Passot G; Pocard M; Salti G; Sardi A; Senthil M; Spiliotis J; Torres-Melero J; Turaga K; Trout R
J Surg Oncol; 2014 Dec; 110(7):779-85. PubMed ID: 25088304
[TBL] [Abstract][Full Text] [Related]
10. Diagnostic Nodes of Patient Selection for Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy Among Colorectal Cancer Patients: A Swiss National Multicenter Survey.
Steffen T; Putora PM; Hübner M; Gloor B; Lehmann K; Kettelhack C; Adamina M; Peterli R; Schmidt J; Ris F; Glatzer M
Clin Colorectal Cancer; 2019 Dec; 18(4):e335-e342. PubMed ID: 31371166
[TBL] [Abstract][Full Text] [Related]
11. Surgical Options for Peritoneal Surface Metastases from Digestive Malignancies-A Comprehensive Review.
Eftimie MA; Potlog G; Alexandrescu ST
Medicina (Kaunas); 2023 Jan; 59(2):. PubMed ID: 36837456
[TBL] [Abstract][Full Text] [Related]
12. Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy in the Management of Colorectal Peritoneal Metastasis.
Hall B; Padussis J; Foster JM
Surg Clin North Am; 2017 Jun; 97(3):671-682. PubMed ID: 28501254
[TBL] [Abstract][Full Text] [Related]
13. Benefit of cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy in patients with isolated peritoneal metastases from colorectal cancer.
Piso P; Stierstorfer K; Gerken M; Klinkhammer-Schalke M
Int J Colorectal Dis; 2018 Nov; 33(11):1559-1567. PubMed ID: 30132068
[TBL] [Abstract][Full Text] [Related]
14. The current practice of cytoreductive surgery and HIPEC for colorectal peritoneal metastases: Results of a worldwide web-based survey of the Peritoneal Surface Oncology Group International (PSOGI).
Bushati M; Rovers KP; Sommariva A; Sugarbaker PH; Morris DL; Yonemura Y; Quadros CA; Somashekhar SP; Ceelen W; Dubé P; Li Y; Verwaal VJ; Glehen O; Piso P; Spiliotis J; Teo MCC; González-Moreno S; Cashin PH; Lehmann K; Deraco M; Moran B; de Hingh IHJT
Eur J Surg Oncol; 2018 Dec; 44(12):1942-1948. PubMed ID: 30075978
[TBL] [Abstract][Full Text] [Related]
15. Age alone is not a barrier to efficacy of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal peritoneal metastases: analysis of 1138 patients from the UK and Ireland Colorectal Peritoneal Metastases Registry.
Kelly ME; O'Sullivan NJ; Bolger JC; Polignano F; Youssef H; Renehan A; Malcomson L; Alves S; Cecil T; Mulsow J; Moran B; Mohamed F;
Br J Cancer; 2023 Jan; 128(1):42-47. PubMed ID: 36347966
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of the peritoneal surface disease severity score (PSDSS) in ovarian cancer patients undergoing cytoreductive surgery and HIPEC: Two pathogenetic types based study.
Yarema R; Fetsych T; Volodko N; Оhorchak M; Petronchak O; Huley R; Mylyan Y; Glehen O
J Surg Oncol; 2018 Jun; 117(8):1806-1812. PubMed ID: 29761503
[TBL] [Abstract][Full Text] [Related]
17. Postoperative complications after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy affect long-term outcome of patients with peritoneal metastases from colorectal cancer: a two-center study of 101 patients.
Baratti D; Kusamura S; Iusco D; Bonomi S; Grassi A; Virzì S; Leo E; Deraco M
Dis Colon Rectum; 2014 Jul; 57(7):858-68. PubMed ID: 24901687
[TBL] [Abstract][Full Text] [Related]
18. Cytoreductive surgery and HIPEC offers similar outcomes in patients with rectal peritoneal metastases compared to colon cancer patients: a matched case control study.
Simkens GA; van Oudheusden TR; Braam HJ; Wiezer MJ; Nienhuijs SW; Rutten HJ; van Ramshorst B; de Hingh IH
J Surg Oncol; 2016 Apr; 113(5):548-53. PubMed ID: 27110701
[TBL] [Abstract][Full Text] [Related]
19. Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy versus cytoreductive surgery alone for colorectal peritoneal metastases (PRODIGE 7): a multicentre, randomised, open-label, phase 3 trial.
Quénet F; Elias D; Roca L; Goéré D; Ghouti L; Pocard M; Facy O; Arvieux C; Lorimier G; Pezet D; Marchal F; Loi V; Meeus P; Juzyna B; de Forges H; Paineau J; Glehen O;
Lancet Oncol; 2021 Feb; 22(2):256-266. PubMed ID: 33476595
[TBL] [Abstract][Full Text] [Related]
20. GECOP-MMC: phase IV randomized clinical trial to evaluate the efficacy of hyperthermic intraperitoneal chemotherapy (HIPEC) with mytomicin-C after complete surgical cytoreduction in patients with colon cancer peritoneal metastases.
Pereira F; Serrano A; Manzanedo I; Pérez-Viejo E; González-Moreno S; González-Bayón L; Arjona-Sánchez A; Torres J; Ramos I; Barrios ME; Cascales P; Morales R; Boldó E; García-Fadrique A; Arteaga X; Gutierrez-Calvo A; Sánchez-García S; Asensio E; Ramírez CP; Artiles M; Vaqué J; Parra PA; Villarejo P; Muñoz-Casares C; Turienzo E; Calero A; Torrejimeno IJ; Prieto I; Galindo J; Borrego V; Marcello ME; Rihuete C; Carrasco J; Gomez-Quiles L
BMC Cancer; 2022 May; 22(1):536. PubMed ID: 35549912
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
